Anti-Human PCSK9 Recombinant Antibody (Bococizumab)
CAT#: TAB-H10
Recombinant Humanized (from mouse) antibody to Human PCSK9. Bococizumab (codenamed RN316)is a monoclonal antibody against PCSK9 designed to reduce LDL cholesterol
Published Data
Tested Data
Gene Expression
Neut
Figure 1 Effect of Antidrug Antibodies on the Durability of Low-Density Lipoprotein (LDL) Cholesterol Lowering and on Plasma Bococizumab and PCSK9 Levels.
Panel A shows the effect of generalized antidrug antibodies (ADAs) on LDL cholesterol levels among the patients who received placebo and among those who received bococizumab, according to whether the patients were ADA-negative throughout the trial, had ADA titers in the lowest two thirds of maximum titers (<1:1176) during follow-up, had ADA titers in the highest third of titers (≥1:1176) during follow-up, or were in the subgroup with ADA titers in the top 10% (≥1:5674). The light blue bars indicate prevalent rates of antibodies at each time point, and the dark blue bars the cumulative incidence of antibody positivity during follow-up. Panel B shows plasma bococizumab levels and Panel C total plasma proprotein convertase subtilisin–kexin type 9 (PCSK9) levels over time, according to the ADA titer. Panel D shows the effect of the neutralizing antibody (NAb) titer on LDL cholesterol levels.
Ridker, P. M., Tardif, J. C., Amarenco, P., Duggan, W., Glynn, R. J., Jukema, J. W.,... & Revkin, J. (2017). Lipid-reduction variability and antidrug-antibody formation with bococizumab. New England Journal of Medicine, 376(16), 1517-1526.
Neut
Figure 2 Variability in the Reduction in LDL Cholesterol Levels, According to the Presence or Absence of Antidrug Antibodies (ADAs).
Waterfall plots for individual patients who received bococizumab show the percent change from baseline in LDL cholesterol levels at 12 weeks (Panel A) and at 52 weeks among the patients in whom antidrug antibodies developed (Panel B) and among those in whom antidrug antibodies did not develop (Panel C). Data are limited to the patients who reported having received bococizumab in the 21 days before the measurement of LDL cholesterol.
Ridker, P. M., Tardif, J. C., Amarenco, P., Duggan, W., Glynn, R. J., Jukema, J. W.,... & Revkin, J. (2017). Lipid-reduction variability and antidrug-antibody formation with bococizumab. New England Journal of Medicine, 376(16), 1517-1526.
❮
❯
SDS-PAGE
Figure 1 Anti-Human PCSK9 Recombinant Antibody (TAB-H10) in SDS-PAGE
Lane 1: Non-reduced
Lane 2: Reduced
SEC-HPLC
Figure 2 Anti-Human PCSK9 Recombinant Antibody (TAB-H10) in HPLC
The purity of TAB-H10 was greater than 95% as determined by SEC-HPLC.
❮
❯
RNA Expression
Figure 1 RNA cell line category: Cell line enhanced (A-431, CACO-2, HaCaT, HeLa, RPTEC TERT1)
Cell lines ordered by descending RNA expression order.
* Image credit: Image credit: Human Protein Atlas https://v21.proteinatlas.org/ENSG00000169174-PCSK9
❮
❯
Specifications
- Host Species
- Human
- Derivation
- Humanized (from mouse)
- Type
- IgG2 - kappa
- Specificity
- PCSK9(proprotein convertase subtilisin/kexin type 9, neural apoptosis-regulated convertase 1, NARC1, NARC-1, proproteine convertase 9, PC9) [Homo sapiens]
- Species Reactivity
- Human
- Applications
- WB, FC, IP, ELISA, Neut, FuncS, IF
- CAS
- 1407495-02-6
- Generic Name
- bococizumab
- ChEMBL
- CHEMBL3137349
- MW
- 145.1 kDa
- Related Disease
- Hypercholesterolemia
Product Property
- Purity
- >95.0% as determined by Analysis by RP-HPLC & analysis by SDS-PAGE.
Applications
- Application Notes
- The PCSK9 antibody has been reported in applications of WB, FC, IP, ELISA, Neut, FuncS, IF.
Target
REVIEWS AND Q&AS
CITATIONS
RESOURCES
DOWNLOADS
RELATED PRODUCTS
Inquiry
Navs
Customer Review
There are currently no Customer reviews or questions for TAB-H10. Click the button above to contact us or submit your feedback about this product.
Cite This Product
To accurately reference this product in your publication, please use the following citation information:
(Creative Biolabs Cat# TAB-H10, RRID: AB_3112024)
Copy citation
Submit Your Publication
Published with our product? Submit your paper and receive a 10% discount on your next order! Share your research to earn exclusive rewards.
Biosimilar Overview
Please refer to Bococizumab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Bococizumab.
Downloadable Resources
Download resources about recombinant antibody development and antibody engineering to boost your research.
Product Notes
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Datasheet
MSDS
COA
Certificate of Analysis LookupTo download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number:
Protocol & Troubleshooting
We have outlined the assay protocols, covering reagents, solutions, procedures, and troubleshooting tips for common issues in order to better assist clients in conducting experiments with our products. View the full list of Protocol & Troubleshooting.
See other products for "Bococizumab"
Afuco™ Anti-PCSK9 ADCC Recombinant Antibody, ADCC Enhanced (AFC-TAB-H10)This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant Humanized (from mouse) antibody to Human PCSK9. It is a monoclonal antibody against PCSK9 designed to reduce LDL cholesterol
DrugMonitor™ Anti-Bococizumab Antibody (VS-1224-YC212)Bococizumab has been used in trials for Dyslipidemia, Hyperlipidemia, Hypercholesterolemia, Cardiovascular Disease, and Heterozygous Familial Hypercholesterolemia treatment and prevention. The DrugMonitor™ Anti-Bococizumab Antibody (VS-1224-YC212) is an anti-drug antibody (ADA) against Bococizumab. This drug-based antibody is raised in mice immunized with the Bococizumab. The anti-Bococizumab antibody may be used in ELISA, pharmacokinetics (PK), and pharmacodynamics (PD) analyses, or serves as a reference standard in ADA assays. It also is an excellent tool for therapeutic drug monitoring, allowing to evaluate the drug efficacy and determine the drug concentration of the Bococizumab in samples.
See other products for "PCSK9"
Select a product category from the dropdown menu below to view related products.
| CAT | Product Name | Application | Type |
|---|---|---|---|
| NABL-097 | Recombinant Anti-human PCSK9 VHH Single Domain Antibody | WB, ELISA, IHC, FC, FuncS | Llama VHH |
| TAB-0080CL-VHH | Anti-Human PCSK9 VHH Single Domain Antibody (TAB-0080CL-VHH) | FuncS, Inhib, FC, WB | Single domain antibody |
| TAB-0081CL-VHH | Anti-Human PCSK9 VHH Single Domain Antibody (TAB-0081CL-VHH) | FuncS, Inhib, FC, WB | Single domain antibody |
| TAB-0082CL-VHH | Anti-Human PCSK9 VHH Single Domain Antibody (TAB-0082CL-VHH) | FuncS, Inhib, FC, WB | Single domain antibody |
| TAB-0083CL-VHH | Anti-Human PCSK9 VHH Single Domain Antibody (TAB-0083CL-VHH) | FuncS, Inhib, FC, WB | Single domain antibody |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| TAB-758 | Anti-PCSK9 Recombinant Antibody (Lodelcizumab) | ELISA, FC, IP, FuncS, IF, Neut, ICC | IgG1 - kappa |
| TAB-H59 | Anti-Human PCSK9 Recombinant Antibody (TAB-H59) | Neut, ELISA, IF, IP, FuncS, FC, ICC | IgG2 - kappa |
| TAB-764CL | Human Anti-PCSK9 Recombinant Antibody (TAB-764CL) | ELISA | Human IgG |
| TAB-0957CL | Anti-Human PCSK9 Recombinant Antibody (h7F8) | ELISA | Humanized antibody |
| TAB-0020CL-F(E) | Anti-Human PCSK9 Recombinant Antibody Fab Fragment (LPD1282/LPD1462 {i.e., antibody 1 F11)) | LDL-c uptake assay | Humanized Antibody |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| PSBL-294 | Human Anti-PCSK9 Recombinant Antibody (clone mAb1); scFv Fragment | WB, Block, FuncS | Human scFv |
| HPAB-0810-CN-S(P) | Human Anti-PCSK9 Recombinant Antibody; scFv Fragment (HPAB-0810-CN-S(P)) | ELISA | Human scFv |
| HPAB-0309-FY-S(P) | Human Anti-PCSK9 Recombinant Antibody (clone 8F5); scFv Fragment | ELISA | Human scFv |
| HPAB-0310-FY-S(P) | Human Anti-PCSK9 Recombinant Antibody (clone 3D1); scFv Fragment | ELISA | Human scFv |
| HPAB-0311-FY-S(P) | Human Anti-PCSK9 Recombinant Antibody (clone 7c4); scFv Fragment | ELISA | Human scFv |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| PFBL-294 | Human Anti-PCSK9 Recombinant Antibody (clone mAb1); Fab Fragment | WB, Block, FuncS | Human Fab |
| HPAB-0051-FY-F(E) | Human Anti-PCSK9 Recombinant Antibody; Fab Fragment (HPAB-0051-FY-F(E)) | Inhib | Human Fab, κ |
| HPAB-0141-FY-F(E) | Human Anti-PCSK9 Recombinant Antibody (clone YW508.20.33); Fab Fragment | FuncS, In vivo | Human Fab |
| HPAB-0152-FY-F(E) | Mouse Anti-PCSK9 Recombinant Antibody; Fab Fragment (HPAB-0152-FY-F(E)) | ELISA | Mouse Fab |
| HPAB-667-FY-F(E) | Human Anti-PCSK9 Recombinant Antibody; Fab Fragment (HPAB-667-FY-F(E)) | Inhib | Human Fab |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| TAB-0953CL | Human Anti-PCSK9 Recombinant Antibody (TAB-0953CL) | ELISA | Human IgG1 |
| TAB-0954CL | Human Anti-PCSK9 Recombinant Antibody (TAB-0954CL) | WB | Human IgG |
| TAB-0955CL | Mouse Anti-PCSK9 Recombinant Antibody (TAB-0955CL) | WB | Mouse IgG |
| TAB-0959CL | Human Anti-PCSK9 Recombinant Antibody (TAB-0959CL) | ELISA, FC | Human antibody |
| TAB-0953CL-S(P) | Human Anti-PCSK9 Recombinant Antibody; scFv Fragment (TAB-0953CL-S(P)) | ELISA | Human scFv |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| TAB-0956CL | Anti-Human PCSK9 Recombinant Antibody (m7F8) | ELISA | |
| TAB-0960CL | Anti-Human PCSK9 Recombinant Antibody (Ab1) | ELISA | Rabbit mAb |
| TAB-0956CL-S(P) | Anti-Human PCSK9 Recombinant Antibody scFv Fragment (m7F8) | ELISA | |
| TAB-0960CL-S(P) | Anti-Human PCSK9 Recombinant Antibody scFv Fragment (Ab1) | ELISA | Rabbit mAb |
| TAB-0956CL-F(E) | Anti-Human PCSK9 Recombinant Antibody Fab Fragment (m7F8) | ELISA |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| PABC-196 | Human Anti-PCSK9 Recombinant Antibody (clone J16) | IF, IP, WB, ELISA | Human IgG |
| HPAB-0240-WJ | Mouse Anti-PCSK9 Recombinant Antibody (HPAB-0240-WJ) | ELISA | Mouse IgG |
| HPAB-0241-WJ | Mouse Anti-PCSK9 Recombinant Antibody (HPAB-0241-WJ) | ELISA | Mouse IgG |
| HPAB-0242-WJ | Mouse Anti-PCSK9 Recombinant Antibody (HPAB-0242-WJ) | ELISA | Mouse IgG |
| HPAB-0243-WJ | Mouse Anti-PCSK9 Recombinant Antibody (HPAB-0243-WJ) | ELISA | Mouse IgG |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| NEUT-1826CQ | Recombinant Human Anti-PCSK9 Antibody, Unconjugated | Neut | IgG1 |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| MOR-2618 | Hi-Affi™ Recombinant Rabbit Anti-PCSK9 Monoclonal Antibody (DS2618AB) | WB | IgG |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| AFC-TAB-758 | Afuco™ Anti-PCSK9 ADCC Recombinant Antibody, ADCC Enhanced (AFC-TAB-758) | ELISA, FC, IP, FuncS, IF, Neut | ADCC enhanced antibody |
| AFC-TAB-H10 | Afuco™ Anti-PCSK9 ADCC Recombinant Antibody, ADCC Enhanced (AFC-TAB-H10) | FC, IP, ELISA, Neut, FuncS | ADCC enhanced antibody |
| AFC-TAB-H59 | Afuco™ Anti-PCSK9 ADCC Recombinant Antibody, ADCC Enhanced (AFC-TAB-H59) | Neut, ELISA, IF, IP, FuncS, FC | ADCC enhanced antibody |
| AFC-TAB-H31 | Afuco™ Anti-PCSK9 Recombinant Antibody (AFC-TAB-H31), ADCC Enhanced | FC, IP, ELISA, Neut, FuncS, IF | Human IgG1, λ |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| VS-0424-XY208 | AbPlus™ Anti-PCSK9 Magnetic Beads (VS-0424-XY208) | IP, Protein Purification |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| VS-0325-FY208 | Human Anti-PCSK9 scFv-Fc Chimera (VS-0325-FY208) | WB, Block | Human IgG1, scFv-Fc |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| VS-0525-XY5250 | Anti-PCSK9 Immunohistochemistry Kit | IHC |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| VS-0525-YC142 | Recombinant Anti-PCSK9 (AA 31-152 x AA 213-219) Biparatopic Antibody, Tandem scFv (Clone 6E2 x Clone 3D5) | ELISA | Tandem scFv |
Specific Inquiry
Add to compare
See Our Custom Production in Action
Popular Products
Application: Neut, ELISA, IF, IP, FuncS, FC, IHC
Application: FC, IP, ELISA, Neut, FuncS, IF, WB
Application: FuncS, IF, Neut, ELISA, FC, IP, ICC
Application: Neut, ELISA, IF, IP, FuncS, FC, ICC
Application: ELISA, SPR, Inhib, FuncS
Application: FC, FRET, Internalization
Application: WB, ELISA, IF, FuncS, Apop, BA
Application: ELISA, Inhib, FuncS
Application: ELISA
Application: ELISA, FC, FuncS
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
Send Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
